Related Experiment Video
Updated: Nov 12, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer
Sara A Collins1, Ashish H Shah2, Derek Ostertag3
1Department of Neurological Surgery, University of California, San Francisco (UCSF), San Francisco, California, United States of America.
Introduction:
The use of tumor-selectively replicating viruses is a rapidly expanding field that is showing considerable promise for cancer treatment. Retroviral replicating vectors (RRV) are unique among the various replication-competent viruses currently being investigated for potential clinical utility, because they permanently integrate into the cancer cell genome and are capable of long-term persistence within tumors. RRV can mediate efficient tumor-specific delivery of prodrug activator genes, and subsequent prodrug treatment leads to synchronized cell killing of infected cancer cells, as well as activation of antitumor immune responses.
Areas Covered:
Here we review preclinical studies supporting bench-to-bedside translation of Toca 511, an optimized RRV for prodrug activator gene therapy, the results from Phase I through III clinical trials to date, and potential future directions for this therapy as well as other clinical candidate RRV.
Expert Opinion:
Toca 511 has shown highly promising results in early-stage clinical trials. This vector progressed to a registrational Phase III trial, but the results announced in late 2019 appeared negative overall. However, the median prodrug dosing schedule was not optimal, and promising possible efficacy was observed in some prespecified subgroups. Further clinical investigation, as well as development of RRV with other transgene payloads, is merited.
Insights
Retroviral replicating vectors (RRV) show promise for cancer treatment by integrating into tumor cells. While Toca 511
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Cancer immunotherapy
Background:
- Retroviral replicating vectors (RRV) offer a unique approach to cancer treatment due to their ability to permanently integrate into the cancer cell genome and persist long-term within tumors.
- RRV can deliver prodrug activator genes specifically to tumors, enabling targeted cancer cell killing and stimulating antitumor immune responses.
Purpose of the Study:
- To review preclinical data and clinical trial results for Toca 511, an optimized RRV for prodrug activator gene therapy.
- To discuss potential future directions for Toca 511 and other clinical candidate RRV therapies.
Main Methods:
- Review of preclinical studies supporting the translation of Toca 511.
- Analysis of data from Phase I through III clinical trials of Toca 511.
- Evaluation of potential future applications and development of RRV therapies.
Main Results:
- Toca 511 demonstrated promising results in early-stage clinical trials.
- A registrational Phase III trial for Toca 511 yielded overall negative results, announced in late 2019.
- Subgroup analyses indicated potential efficacy, suggesting suboptimal prodrug dosing may have impacted outcomes.
Conclusions:
- Despite setbacks, further clinical investigation of Toca 511 is warranted, particularly exploring optimized dosing schedules.
- Development of RRV with alternative transgene payloads holds potential for advancing cancer treatment.
- The field of tumor-selectively replicating viruses for cancer therapy continues to show promise.
Related Concept Videos
00:59Gene Therapy
01:51Mechanisms of Retrovirus-induced Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Preclinical Development: Overview